GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the ...

Cassandra Smith has rheumatoid arthritis (RA) and knows all too well how debilitating the autoimmune condition can be. Her ...

A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

While these medications aren’t approved for chronic inflammatory diseases such as rheumatoid arthritis (RA), many people with RA have been prescribed a GLP-1 to manage a coexisting condition.

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Among adults with diagnosed diabetes, the likelihood of using GLP-1 RA injectables was higher for those who took insulin or oral glucose-lowering medications versus those who did not (31.3 and 28. ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

There are several reasons that GLP-1 RA medications are currently expensive. One is research: GLP-1 medications are the result of extensive research, making them more expensive than many older drugs.

GLP-1 RA injectable use prevalence among adults with diabetes was 26.5% in 2024, but rates were higher in some age and racial groups.